Navigation Links
Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Date:8/28/2007

ood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Under the worldwide co- development and commercialization agreement entered into in June 2006, HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $92.5 million received to date and a $40 million payment expected in September 2007.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. An estimated 170 million people worldwide are infected with the virus, including nearly 4 million people in the United States. When detectable levels of the hepatitis C virus persist in the blood for at least six months, a person is diagnosed as having chronic hepatitis C. The hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are under way.

In J
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... 22, 2014 Investor-Edge has initiated ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,419.48, up 2.40%, the ...
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
... Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta- based ... entered into a $10 million common,stock purchase agreement ... investor., The Company may sell up to ... from time to time over a 25-month period ...
... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... Food and Drug Administration ("FDA") of an,Investigational Device ... SEPET(TM), Arbios, extracorporeal (outside the body) liver assist,device ... from,chronic liver disease., "We are pleased to ...
Cached Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... responding to the devastation across Greece caused by this ... series of crisis map products based on satellite acquisitions ... assessment efforts following the activation of the International Charter ... people were killed and thousands left homeless in the ...
... 21 Baxa Corporation, a leading,provider of systems ... announces the addition of two new international product,distributors. ... Colombia and Pentafarma & Co. in The Dominican ... reach and expand product promotion in South,America and ...
... from DCM and Split Rock Partners, PALO ALTO, ... of its website. Caring.com will offer original "how,to" guides, ... and a community of people in caring situations, to ... million adults who are,caring for an aging relative in ...
... scientific peer review, will gather in Helsinki on 27 September ... from the fourth and final Call of the European Young ... to create teams in Europe to focus on cutting-edge science. ... from around the world to create their own research teams ...
... drugs plus insulin works best, researchers say , , FRIDAY, ... tell which insulin-plus-drug regimen might best control type 2 ... the three strategies tested coming out on top. , ... in the study can be recommended" as being superior ...
... Waltham, MA -- Brandeis neuroscientist Gina Turrigiano has been ... Award, a five-year grant totaling $2.5 million. She is ... competitive award. , According to NIH, the award ... who propose pioneering approaches to major challenges in biomedical ...
Cached Medicine News:Health News:Greeks get space-based help in wake of deadly fires 2Health News:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 3Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 2Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 3Health News:No Clear Winner in Diabetes Treatment Trial 2Health News:No Clear Winner in Diabetes Treatment Trial 3
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
Inquire...
Inquire...
Medicine Products: